|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Updated Clinical Trial and FDA Decision Calendars
OSIP
|
|
|
-9.80%
in
247 days
Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars. <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through 3/20/09. The FDA Calendar includes the following information: company name, ticker, decision date, and descrip...
|
OSI Pharmaceuticals Inc.
OSIP
|
|
|
-34.83%
in
446 days
OSI Pharmaceuticals, Inc., a biotechnology company, discovers, develops, and commercializes molecular targeted therapies for oncology, diabetes, and obesity in the United States and internationally. Its flagship product, Tarceva (erlotinib) is a small molecule inhibitor of the epidermal growth factor receptor, which is used for the treatment of advanced non-small cell lung cancer, as well as for the treatment of patients with locally advanced and metastatic pancreatic cancer in combination with the chemotherapy agent, gemcitabine. The company also offers Macugen for the treatment of neovasc...
|
OSIP is a HOLD
OSIP
OSIP is a HOLD
OSIP
|
|
|
+0.28%
in
12 days
(closed on 06/23/07)
|
From the Blogosphere
Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and Bank of America Corporation – Press Releases
|
|
|
For Immediate Release Chicago, IL – November 11, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Enzon (ENZN), Merck (MRK), OSI Pharmaceuticals (OSIP), Pfizer (PFE) and Bank of America Corporation (BAC). Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 Here are highlights from Tuesday’s Analyst Blog: <><>Enzon Beats,...
|
Enzon Beats, Announces Sell-off – Analyst Blog
|
|
|
Enzon (ENZN) achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent. The company reported revenues of $44.6 million, a decline of 9% compared to $48.8 million reported in the third quarter of 2008.
Enzon records revenues from three sources -- products, royalties and contract manufacturing. The three segments recorded a decline of 1%, 6% and 56%, respectively, compared to the year-ago period.
Enzon has four marketed products -- Oncaspar for the treatment of acute lymphoblastic leukemia...
|
As Galleon Investors Flee, Some Tech Stocks Could Suffer
|
|
|
The spreading Galleon Group insider trading scandal has begun causing problems for some stocks in which the hedge fund operator has large holdings, the Wall Street Journal notes. The Journal notes that investors have sought to withdraw $1.3 billion of the $3.7 billion in assets managed by the hedge fund group. The WSJ also noted that two large brokerage firms - Bank of America Merrill Lynch and Barclays - have told Galleon they will no longer trade with the firm. According to StreetSight.net, at June 30 Galleon held more than 2% of the outstanding shares of eight different stocks: <><><>Applied Ener...
|
Who Will Buy Spectrum Pharmacueticals?
<>There seems to be a lot of speculation on the chances of Spectrum Pharma (SPPI) being acquired over the coming months. I personally don't think it will happen, but there are a few companies that could be interested. Bayer (BYERF.PK) will always be mentioned because of the fact they sell Zevalin in Europe, but Bayer did just divest two oncology drugs to Genzyme (GENZ), Fludara and Leukine, which makes me think that oncology is not where they want to focus their company. Allergan (AGN) should also be mentioned because of their partnership of bladder cancer drug EOquin with Spectrum, the drug...
|
OSI Pharmaceutical Gets a Boost from Cancer Drug
By Jon "DRJ" Najarian <> Lung Cancer Drug Advances
OSI Pharmaceutical (OSIP) and Roche subsidiary Genentech (DNA) announced that a pivotal Phase III study of Tarceva met a key secondary endpoint of extending overall survival in patients with advanced lung cancer who received the drug immediately after initial chemotherapy. A statistically significant improvement in overall survival was seen in this final analysis of the total patient population. OSIP and Genentech will present during the 13th World Conference on Lung Cancer to be held July 31 to Aug. 4 in San Francisco. OSIP closed at $28.44 Fri...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on OSIP |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About OSI Pharmaceuticals Inc.
- Answers.com
